Eliglustat and Xanax

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Before using eliglustat, you should have received a test to determine your CYP450 2D6 genotype, which lets the doctor know whether or not you can take the medication and at what dosage. Depending on your CYP450 2D6 genotype and what other medications you may be on, using eliglustat together with ALPRAZolam may not be recommended at all, or a dosage adjustment of eliglustat may be needed. Treatment with ALPRAZolam can increase the blood levels of eliglustat. This may increase the risk of serious and potentially life-threatening cardiac side effects such as irregular heart rhythm, heart block, and cardiac arrest. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the interaction, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, slow heart rate, weak pulse, or heart palpitations during treatment with eliglustat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes. Simulations using physiologically-based pharmacokinetic (PBPK) models suggest that the potent CYP450 3A4 inhibitor ketoconazole may increase eliglustat systemic exposure (AUC) by 4.4-, 5.4- and 6.2-fold in CYP450 2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs) and poor metabolizers (PMs), respectively, while the moderate CYP450 3A4 inhibitor fluconazole may increase eliglustat AUC by 3.2-, 2.9- and 3.0-fold, respectively. No data are available for use with other, less potent inhibitors.

MANAGEMENT: Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.

Eliglustat

Generic Name: eliglustat

Brand name: Cerdelga

Synonyms: n.a.

What is Eliglustat?

Xanax

Generic Name: alprazolam

Brand name: Niravam, Xanax, Xanax XR, Alprazolam Intensol

Synonyms: n.a.

What is Xanax?